Introduction
Total knee arthroplasty (TKA) is associated with significant perioperative blood loss and high transfusion rate of 11e21%. 1 Allogenic blood transfusion may lead to a number of adverse events, including transfusion reaction, volume overload, electrolyte imbalance and disease transmission. Blood transfusion may also increase the chance of postoperative bacterial infections, mainly due to its effect on immunosuppression. 2 Literature has suggested different strategies in lowering blood transfusion rate, including preoperative autologous transfusion, hypotensive anaesthesia, drain clamping, application of fibrin tissue adhesive, compressive bandage and cryotherapy. 3e7 These methods demonstrate reduction in blood loss but associated with high cost and complications. 8, 9 Tranexamic acid (TA) is an antifibrinolytic agent used for controlling bleeding in various surgical situations. 10e12 Many studies have proven its efficacy and safety in reduction of blood loss in total joint replacement. 13e17 Different routes and dosage of TA administrations have been reported. The benefits of topical TA include ease of administration, minimal systemic side effects, low systemic absorption and maximal local concentration. 13 Recent trials and meta-analyses suggested that topical TA has similar efficacy as intravenous route without increased risk of thromboembolic event. 18, 19 Despite the well-proven efficacy of TA, there were no clinical studies published on Southern Chinese population comparing the use of topical TA in primary TKA.
The purpose of this study was to investigate the effect of intraarticular TA injection in primary TKA in Southern Chinese population.
Methods
This retrospective study was conducted from July 2015 to September 2016, recruiting 296 patients undergoing primary cemented TKA in Pok Oi Hospital, Hong Kong. The TA group included all patients since January 2016 after starting the use of topical TA (n ¼ 154), and the control group consisted of all patients in the 6 months before the implementation (n ¼ 142). Exclusion criteria included allergy to TA, patients with severe ischaemic cardiopathy, known coagulopathy, severe pulmonary and renal insufficiency, history of arterial or venous thromboembolic disease or haematological disorder. Same exclusion criteria have been applied to both TA and control groups.
All TKAs were performed under a standard medial parapatellar approach with tourniquet. The implants were the NexGen Legacy PS knee (Zimmer Biomat, Warsaw, IN) or Attune PS (DePuy Synthes, Warsaw, IN). Intramedullary (IM) guide was used for femoral cutting, and extramedullary or toffset 15mm IM guide was used for tibial cutting. The femoral canal was sealed by the autologous bone plug after the use of intramedullary alignment. After cementation of all components and placement of the implant, haemostasis was performed with tourniquet released. The TA group received intraarticular administration of 1.5 g of TA (diluted to 50 mL with normal saline) after closure of arthrotomy. The injection was done through the incision wound into the suprapatellar pouch. The drain bottle with low suction pressure (200 mmHg) was clamped for 2 hours before release. All drains were removed between 24 and 48 hours, and the drain output was monitored. Haemoglobin (Hgb) level was checked immediately after operation and on postoperative Day 1 and Day 5. Transfusion was triggered if Hgb level < 7.0 g/dL or symptomatic anaemia was presented. The same transfusion trigger was used in two groups, according to our department transfusion guideline in arthroplasty. Postoperative thromboembolic prophylaxis was standardised in both TA and control groups. All patients were given foot pumps and antiembolic stockings until mobilisation started, and subcutaneous enoxaparin was prescribed as chemical prophylaxis for patients with the body mass index >27 kg/m 2 . Doppler ultrasound and computed tomography pulmonary angiogram were recommended if patients were clinically suspicious of thromboembolic events. All patients were discharged if they were able to ambulate independently with aids after physiotherapy and occupational therapy.
Different outcomes were measured, including transfusion rate, maximum Hgb drop (difference between preoperative Hgb and the lowest postoperative Hgb), maximum haematocrit drop (difference between preoperative and the lowest postoperative haematocrit level), volume of drain output, length of hospital stay and any thromboembolic complications.
Sample size
The sample size was estimated by using the primary outcome of Hgb drop between the TA group and control group. By reviewing the data of patients admitted during January to June 2015 into Pok Oi Hospital for unilateral TKA (before implementation of topical TA), the mean drop in Hgb level was 3.15 (±1.79 g/dL standard deviation). Wong et al 16 published a randomised controlled trial in 2010 using 1.5 g of topical TA and suggested a mean reduction in Hgb drop level by around 1 g/dL, compared with the placebo group.
Assuming that the level of alpha was 0.05 and power was 0.8, the sample size required for each group was 50. The total sample size required should be at least 100.
Statistical analysis
Independent t test was used to analyse parametric numeric data, and the ManneWhitney U-test was used for nonparametric numeric data. The Chi-square or Fisher's exact test was used to compare the groups for categorical variables as appropriates. All differences were considered to be significant if p value was <0.05. The analysis was carried out using Statistical Package for Social Science (IBM SPSS version 23.00 for windows).
Results
Patients' demographic data, including age, sex, weight, body mass index, American Society of Anaesthesiologists status, operation time, preoperative Hgb and haematocrit level, use of IM/ extramedullary guide for tibial cutting and chemoprophylaxis use, were compared in the TA group (n ¼ 154) and control group (n ¼ 142). There were no significant differences between the two groups (refer to Table 1) .
Maximum Hgb and haematocrit drop were significantly lower in the TA group (p < 0.001). The transfusion rate was 3.2% in the TA group (5 of 154 patients) and 23.9% in the control group (34 of 142 patients). The difference was statistically significant. The length of hospital stay was also significantly shorter in the TA group, dropping by 2 days. For drain output, it was reduced by 77 mL in the patients receiving TA, and it showed significant difference. There were two cases of pulmonary embolism and one case of periprosthetic joint infection in the control group. No thromboembolic complication was reported in the TA group (refer to Table 2 ).
Discussion
Our study demonstrated a significant reduction in the Hgb drop (2.76 g/dL vs. 3.62 g/dL), haematocrit drop (0.0876 vs. 0.112), transfusion rate (3.2% vs. 23.9%) and length of stay (9 days vs. Our patients in this study belonged to grades IeIII. b Data concerning the use of IM or EM guide for tibial cutting in four patients were not specified in the operation (OT) record. (2 patients from the TA group and 2 patients from the control group).
11 days) in the TA group compared with those in the control group. These results are consistent and supported by other authors. 13, 14, 17, 20 Cid et al published a meta-analysis including nine randomised controlled trials. He concluded that the incidence of blood transfusion was not different in both low-dose (15e35 mg/ kg) and high-dose (135e150 mg/kg) groups. 21 Therefore, in our study, a relative low dose of 1,500 mg of TA was used compared with that used in other trials and reports. Indeed, the transfusion rate dropped from 27.5% in the control group to 3.6% in the TA group. Ishida et al adopted similar technique by intraarticular injection of TA followed by drain-clamping method. They revealed reduction not only in Hgb drop level but also the drain volume.
14 Our study also successfully demonstrated a reduction in the drain output (199 mL vs. 276 mL) by around 77 mL postoperatively in patients receiving TA, which is statistically significant. In fact, the difference in the drain output between the two groups was expected to be greater. This could be explained by our approach involving intraarticular injection of 50 mL of TA, which will eventually escape through the drain. TA is a commonly used antifibrinolytic agent in different surgical interventions since 1960s. It acts by reversibly binding receptor sites on plasminogen or plasmin, which prevents degradation of fibrin. There have been reports concerned about the risk of pulmonary embolism and deep vein thrombosis in certain high-risk population. To minimise the thromboembolic risk, we have excluded those with severe cardiac condition, history of thromboembolic disease and known haematological disorder. In this study, there were no reported incidents of venous thromboembolic event in patients receiving TA. We believe that the low dosage and topical application of TA leads to lower systemic absorption and thus a safer alternative than intravenous administration. 13 However, Doppler ultrasound or venography is not routinely performed in all our cases. There are limitations in our study. First, the two groups of patients were recruited from different time frames. Although their demographic data were compared and showed no statistical difference, we cannot ensure the absence of other confounding factors, such as surgeon factor and the patient's medical comorbidities. Besides, the blood loss control in total joint arthroplasty could be affected by many factors. Particularly, preoperative anaemia showed a strong association with the need of allogenic blood transfusion in multiple studies. 22e24 We did not exclude any patients with comorbid anaemia and low preoperative Hgb level in our study. Despite demonstrating no statistical difference in the preoperative Hgb level between the two groups, this may still influence our outcome. Finally, our study mainly focuses on the effect on immediate postoperative blood loss and complications. However, we may need follow-up and monitoring to understand the long-term benefits and adverse effects of TA. Further studies to investigate on the effect of TA on one-stage bilateral TKA and total hip arthroplasty could be considered.
Conclusion
This study supports the use of topical TA in reducing postoperative blood loss for primary TKA. We consider this technique to be safe and efficient to our patients undergoing TKA.
Conflicts of interest
All authors declare no conflicts of interest.
